540204 — Eiko Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹751.74m
- IN₹673.36m
- IN₹525.71m
Annual cashflow statement for Eiko Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | R2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | Interim Report | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 9.42 | 10.3 | 9.84 | 30.6 | 71.2 |
| Depreciation | |||||
| Non-Cash Items | -1.78 | -6.08 | -0.397 | -8.9 | -7.96 |
| Extraordinary Items | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -90.5 | 31.7 | -86.9 | 0.115 | -14.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -77.3 | 42.2 | -70.8 | 29.2 | 59.1 |
| Capital Expenditures | -1.55 | -2.25 | -3.46 | -103 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 7.47 | 22.2 | -2.02 | -11.5 | -86.3 |
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 5.92 | 20 | -5.49 | -114 | -86.3 |
| Financing Cash Flow Items | -4.64 | -1.5 | -1.42 | -1.54 | -3.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 32.8 | -47 | 204 | 69.6 | 82.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -38.5 | 15.2 | 127 | -15.7 | 18.3 |